EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Gross Margin
EyePoint Pharmaceuticals Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
462.8m USD |
91%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
831.3B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.7B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
210.9B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
189.1B CHF |
75%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
163.2B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.3B USD |
79%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.7B EUR |
70%
|
EyePoint Pharmaceuticals Inc
Glance View
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2005-01-27. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The firm has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The firm is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on EyePoint Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 91.4%.
You don't have any saved screeners yet